Loss of Chromosome 17 in Ovarian Cancer
Author Information
Author(s): J Pappl, B Csokay, P Boszel, Z Zalay, J Toth, B Ponder, E Olah
Primary Institution: National Institute of Oncology, Department of Molecular Biology
Hypothesis
Is loss of heterozygosity on chromosome 17 common in ovarian carcinomas, and does it vary by histological subtype?
Conclusion
Loss of chromosome 17 is a frequent event in ovarian carcinomas, particularly in serous and transitional cell subtypes.
Supporting Evidence
- 50% of malignant cases showed loss of heterozygosity at D17S5.
- 30% of carcinomas examined had loss of the entire chromosome 17.
- 67% of malignant cases showed allele loss at TP53.
- 80% of serous tumors exhibited loss of heterozygosity on chromosome 17.
- c-erbB-2 amplification was found in 32% of the carcinomas tested.
Takeaway
This study looked at ovarian cancer samples and found that losing part of chromosome 17 happens a lot, especially in certain types of tumors.
Methodology
The study examined loss of heterozygosity on chromosome 17 using ten polymorphic markers in 55 ovarian tumor samples.
Limitations
The study's sample size was relatively small and focused only on specific histological subtypes.
Participant Demographics
The study included 55 patients with sporadic ovarian tumors, with various histological subtypes.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website